Recognizing Rare Disease Day: Advancing Hope, Access and Innovation

On Rare Disease Day, we recognize the more than 300 million people worldwide living with rare conditions—individuals who often face long diagnostic journeys, limited treatment options, and barriers to consistent care. At EVERSANA, supporting this community is central to who we are and the work we do every day.  

How is EVERSANA advancing rare disease commercialization? 

Across EVERSANA, our teams bring deep, specialized experience to rare and ultra‑rare therapy commercialization. Today, we support: 

• 25+ rare disease states across traditional, cell and gene therapies 

• More than 140 rare disease products 

• Patient populations as small as 80 individuals worldwide 

• A growing number of ultra‑rare conditions including Friedreich’s ataxia, ALS, TK2 deficiency and cystinosis 

Every program starts with understanding patient needs. We work to accelerate diagnosis, strengthen access, streamline onboarding, and deliver personalized adherence support. Our standards are validated through industry‑leading accreditation, including URAC Specialty Pharmacy 5.0 and the URAC Rare Disease Center of Excellence Certification. 

How are we helping clinicians detect rare diseases earlier? 

We continue to advance innovation that improves early identification and care. Through our collaboration with the National Institutes of Health (NIH), we are building a real‑time clinical decision support framework that uses advanced AI, machine learning, and RAG‑LLM models. This work supports clinicians by surfacing key diagnostic insights earlier and more accurately, even for diseases without ICD‑10 codes. 

Our research also includes a 14‑disease economic burden study—a unique role for a commercialization partner and an important foundation for improving patient support. 

What does rare disease impact look like in practice? 

A recent example is our collaboration with Precigen on the launch of Papzimeos, the first FDA‑approved therapy for recurrent respiratory papillomatosis (RRP). For patients who have relied on repeated surgeries, Papzimeos represents a meaningful step forward and demonstrates what becomes possible when innovative science is paired with an integrated commercialization model built for speed and precision. 

This launch joins more than one hundred rare disease programs supported across EVERSANA, reflecting a repeatable and scalable approach that helps emerging and established companies bring breakthrough therapies to patients faster and more efficiently. 

Why does rare disease work matter to our teams? 

Across EVERSANA, our leaders and teams share a deep sense of purpose in supporting the rare disease community. Their voices, perspectives, and passion drive our work and inspire our continued investment in the patients, families and partners we serve. 

Discover How We Are Advancing the Commercialization of Rare & Orphan Drugs